Epiminder has received FDA authorisation through the De Novo classification for its implantable continuous EEG monitoring ...

The ANNs correctly classified all samples and identified the genes most relevant to the classification. Expression of several of these genes has been reported in SRBCTs, but most have not been ...

MELBOURNE, Australia and DALLAS, April 23, 2025 /PRNewswire/ -- Epiminder, a pioneering medical device and information solutions company, today announced ...

Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.